Clinical Trials Logo

Spinal Muscular Atrophy clinical trials

View clinical trials related to Spinal Muscular Atrophy.

Filter by:

NCT ID: NCT03554343 Completed - Clinical trials for Spinal Muscular Atrophy

Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium

Start date: March 5, 2018
Phase:
Study type: Observational

Medico-economic study of Newborn screening of Spinal Muscular Atrophy

NCT ID: NCT03520179 Recruiting - Clinical trials for Spinal Muscular Atrophy

Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA)

SMA-REACH
Start date: December 17, 2013
Phase:
Study type: Observational [Patient Registry]

The SMA REACH UK Network is a national and international partnership between doctors and therapists involved in the care of children and adults with Spinal Muscular Atrophy. This network is supported by Biogen and SMA UK.

NCT ID: NCT03505099 Completed - Clinical trials for Spinal Muscular Atrophy

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2

SPR1NT
Start date: April 2, 2018
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2

NCT ID: NCT03381729 Terminated - Clinical trials for Spinal Muscular Atrophy

Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy

STRONG
Start date: December 14, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to evaluate the safety and tolerability of intrathecal administration of onasemnogene abeparvovec-xioi in infants and children with Spinal Muscular Atrophy with 3 copies of SMN2 and deletion of SMN1.

NCT ID: NCT03339830 Completed - Clinical trials for Spinal Muscular Atrophy

European Registry of Patients With Infantile-onset Spinal Muscular Atrophy

Start date: October 10, 2017
Phase:
Study type: Observational [Patient Registry]

IO-SMA-Registry is a prospective, longitudinal and observational study which objective is to collect prospectively information on longevity, psychomotor development and respiratory function of patients with infantile-onset spinal muscular atrophy.

NCT ID: NCT03300869 Recruiting - Clinical trials for Spinal Muscular Atrophy

Natural History of Types 2 and 3 SMA in Taiwan

Start date: September 1, 2017
Phase:
Study type: Observational

The primary objective of this study is to investigate the natural history of spinal muscular atrophy (SMA) types 2 and 3 patients in Taiwan. This study will provide further insights into the clinical course SMA. Several analyses will be conducted regarding overall survival, demographic characteristics, motor function, respiratory and nutritional support, and genotype and phenotype correlation.

NCT ID: NCT03223051 Completed - Clinical trials for Spinal Muscular Atrophy

Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy

ExplorASI
Start date: September 7, 2017
Phase: N/A
Study type: Interventional

The aim of this randomized study is to develop a new motor assessment of space exploration in a 2D environment with upper limbs for children with spinal muscular atrophy 1 and 2 from 3 until 16 years old.

NCT ID: NCT03217578 Recruiting - Clinical trials for Spinal Muscular Atrophy

Neonatal Spinal Muscular Atrophy (SMA) Screening

SMA
Start date: September 1, 2017
Phase:
Study type: Observational

Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA. The dried blood spots of routine newborn screening samples will be used to test if neonates have lost 2 copies of SMN1 gene. If neonates have positive SMA screening test, further confirmation with multiplex ligation-dependent probe amplification (MLPA) test and prospective motor function monitoring including physical and neurological examinations will be proved to make SMA confirmation. For any confirmed SMA patient, genetic counseling and standard of care will be proved.

NCT ID: NCT03032172 Active, not recruiting - Clinical trials for Spinal Muscular Atrophy

A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

Jewelfish
Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA) previously enrolled in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previously treated with nusinersen, olesoxime or AVXS-101.

NCT ID: NCT02941328 Completed - Clinical trials for Spinal Muscular Atrophy

SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4

SPACE
Start date: December 2015
Phase: Phase 2
Study type: Interventional

A trial investigating the effects of pyridostigmine (mestinon) versus a placebo in a double-blind cross over trial in patients with hereditary proximal spinal muscular atrophy (SMA) types 2, 3 and 4.